Fleckenstein-Grün et al., 1994 - Google Patents
Role of calcium in arteriosclerosis—experimental evaluation of antiarteriosclerotic potencies of Ca antagonistsFleckenstein-Grün et al., 1994
- Document ID
- 15751470960415397285
- Author
- Fleckenstein-Grün G
- Thimm F
- Frey M
- Czirfusz A
- Publication year
- Publication venue
- Arteriosclerosis: New Insights into Pathogenetic Mechanisms and Prevention
External Links
Snippet
Chemical microanalyses of conventional human coronary artery plaques (stages I-III [WHO]) revealed the correlation between progressive mural Ca overload up to excessive degrees, and the severity of plaque formation, whereas only small amounts of cholesterol were found …
- 230000003042 antagnostic 0 title abstract description 40
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K8/00—Cosmetic or similar toilet preparations
- A61K8/18—Cosmetic or similar toilet preparations characterised by the composition
- A61K8/30—Cosmetic or similar toilet preparations characterised by the composition containing organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K8/00—Cosmetic or similar toilet preparations
- A61K8/02—Cosmetic or similar toilet preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Napoli et al. | Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension | |
| US20070037860A1 (en) | Synergistic effects of amlodipine and atorvastatin metabolite as a basis for combination therapy | |
| Fuhrman et al. | Licorice extract and its major polyphenol glabridin protect low-density lipoprotein against lipid peroxidation: in vitro and ex vivo studies in humans and in atherosclerotic apolipoprotein E-deficient mice | |
| Upston et al. | Tocopherol‐mediated peroxidation of lipoproteins: implications for vitamin E as a potential antiatherogenic supplement | |
| Hendrich et al. | Lipids as a target for drugs modulating multidrug resistance of cancer cells | |
| Boigk et al. | Silymarin retards collagen accumulation in early and advanced biliary fibrosis secondary to complete bile duct obliteration in rats | |
| Mason et al. | Antioxidant properties of calcium antagonists related to membrane biophysical interactions | |
| Kerry et al. | The isoflavone genistein inhibits copper and peroxyl radical mediated low density lipoprotein oxidation in vitro | |
| Schuurhuis et al. | Quantitative determination of factors contributing to doxorubicin resistance in multidrug-resistant cells | |
| Sobal et al. | Calcium antagonists as inhibitors ofin vitro low density lipoprotein oxidation and glycation | |
| Tulenko et al. | Cholesterol, calcium and atherosclerosis: is there a role for calcium channel blockers in atheroprotection? | |
| Avogaro et al. | Some questions concerning a small, more electronegative LDL circulating in human plasma | |
| Fleckenstein-Grün et al. | Role of calcium in arteriosclerosis—experimental evaluation of antiarteriosclerotic potencies of Ca antagonists | |
| Arrol et al. | Vitamin E supplementation increases the resistance of both LDL and HDL to oxidation and increases cholesteryl ester transfer activity | |
| Hussein et al. | Valsartan therapy has additive anti-oxidative effect to that of fluvastatin therapy against low-density lipoprotein oxidation: studies in hypercholesterolemic and hypertensive patients | |
| Breugnot et al. | Calcium antagonists prevent monocyte and endothelial cell-induced modification of low density lipoproteins | |
| Ganini et al. | Absence of an effect of vitamin E on protein and lipid radical formation during lipoperoxidation of LDL by lipoxygenase | |
| Berkels et al. | Different antioxidative potencies of dihydropyridine calcium channel modulators in various models | |
| Zapolska-Downar et al. | Ibuprofen protects low density lipoproteins against oxidative modification | |
| Gouazé et al. | Effect of nicotine and cotinine on the susceptibility to in vitro oxidation of LDL in healthy non smokers and smokers | |
| Witztum | The role of oxidized LDL in the atherogenic process | |
| EP1173172B1 (en) | Synergistic effects of amlodipine and the hydroxylated metabolite of atorvastatin | |
| Edwards et al. | Effect of low-dose cyclosporin on plasma lipoproteins and markers of cholestasis in patients with psoriasis | |
| Borghesi et al. | Nonprotective effects of extracellular metallothionein | |
| Zhang et al. | Effects of ICRF-186 [(L) 1, 2-bis (3, 5-dioxopiperazinyl-1-yl) propane] on the toxicity of doxorubicin in spontaneously hypertensive rats |